CA2776835A1 - Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor - Google Patents

Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor Download PDF

Info

Publication number
CA2776835A1
CA2776835A1 CA2776835A CA2776835A CA2776835A1 CA 2776835 A1 CA2776835 A1 CA 2776835A1 CA 2776835 A CA2776835 A CA 2776835A CA 2776835 A CA2776835 A CA 2776835A CA 2776835 A1 CA2776835 A1 CA 2776835A1
Authority
CA
Canada
Prior art keywords
methyl
esi
diazabicyclo
nonan
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2776835A
Other languages
English (en)
French (fr)
Inventor
Paul David Ratcliffe
Thomas Russell Clarkson
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
MSD Oss BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD Oss BV filed Critical MSD Oss BV
Publication of CA2776835A1 publication Critical patent/CA2776835A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2776835A 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor Abandoned CA2776835A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
EP09172872.5 2009-10-13
US61/251,101 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
CA2776835A1 true CA2776835A1 (en) 2011-04-21

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2776835A Abandoned CA2776835A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Country Status (12)

Country Link
US (1) US8841289B2 (enExample)
EP (1) EP2488520B1 (enExample)
JP (1) JP2013507417A (enExample)
KR (1) KR20120100913A (enExample)
CN (1) CN102666540A (enExample)
AU (1) AU2010305825A1 (enExample)
BR (1) BR112012008518A2 (enExample)
CA (1) CA2776835A1 (enExample)
IN (1) IN2012DN02968A (enExample)
MX (1) MX2012004289A (enExample)
RU (1) RU2012119488A (enExample)
WO (1) WO2011045258A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2563232T3 (es) 2011-07-29 2016-03-11 Taisho Pharmaceutical Co., Ltd. Compuesto de amidina o sal del mismo
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US20150164858A1 (en) * 2012-05-22 2015-06-18 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP3191459A1 (en) 2014-09-05 2017-07-19 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
HK1248222A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
HK1248220A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
CA2988968A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
US10500205B2 (en) 2015-12-09 2019-12-10 Cadent Therapeutics, Inc. Thienopyrimidinone NMDA receptor modulators and uses thereof
ES2821010T3 (es) 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
CA3105174A1 (en) * 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
CA3108519A1 (en) 2018-08-03 2020-04-30 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198188A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
EP4204418A1 (en) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
TW202539670A (zh) * 2024-02-23 2025-10-16 大陸商海思科醫藥集團股份有限公司 Braf抑制劑的製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2005504730A (ja) * 2001-04-20 2005-02-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｇｓｋ−３インヒビターとして有用な組成物
WO2003062235A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
PT1910333E (pt) * 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
CN101600698B (zh) 2006-09-11 2012-01-11 欧加农股份有限公司;药典有限责任公司 喹唑啉酮和异喹啉酮乙酰胺衍生物
JP5313919B2 (ja) * 2006-12-27 2013-10-09 サノフイ 新規な置換イソキノリン及びイソキノリノン誘導体
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
BRPI0820259A2 (pt) * 2007-11-14 2015-06-16 Neurosearch As Derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, composição farmacêutica, uso do derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, e, método de tratamento, prevenção ou alívio de uma doença ou uma desordem ou uma condição de um corpo de animal vivo
WO2009107236A1 (ja) 2008-02-29 2009-09-03 テクノコアインターナショナル株式会社 パック電池の充電装置及びパック電池の品質判定装置

Also Published As

Publication number Publication date
EP2488520A1 (en) 2012-08-22
WO2011045258A1 (en) 2011-04-21
AU2010305825A1 (en) 2012-04-19
JP2013507417A (ja) 2013-03-04
CN102666540A (zh) 2012-09-12
US8841289B2 (en) 2014-09-23
BR112012008518A2 (pt) 2016-04-05
MX2012004289A (es) 2012-06-12
US20120208796A1 (en) 2012-08-16
EP2488520B1 (en) 2015-09-02
KR20120100913A (ko) 2012-09-12
IN2012DN02968A (enExample) 2015-07-31
RU2012119488A (ru) 2013-11-20

Similar Documents

Publication Publication Date Title
EP2488520B1 (en) Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
US10752624B2 (en) Kinase inhibitors
CN113061132B (zh) 一类稠环内酰胺类化合物、制备方法和用途
JP6673920B2 (ja) Ｐａｒｇ阻害化合物
US9637491B2 (en) Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
AU2008228303B2 (en) Substituted pyrimidodiazepines useful as PLK1 inhibitors
JP2006505509A (ja) 受容体型キナーゼモジュレーターおよびその使用方法
AU2007287319A1 (en) Pyrimidone compounds as GSK-3 inhibitors
RS59106B1 (sr) Derivati pirazol aminopirimidina kao lrrk2 modulatori
KR20090038895A (ko) 융합된 피리미도 화합물
KR20150016535A (ko) 파킨슨 병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리딘 유도체
WO2018102325A1 (en) Tricyclic rho kinase inhibitors
JP7801084B2 (ja) Ｅｇｆｒ阻害剤としてのインドリン化合物及び誘導体
WO2012085167A1 (en) Metabotropic glutamate receptor modulators
KR20150119926A (ko) 비시클로 2,3-벤조디아제핀 및 스피로시클릭 치환된 2,3-벤조디아제핀
WO2013153539A1 (en) Tricyclic compounds as tec kinase inhibitors
CA2674087A1 (en) 6' substituted compounds having 5-ht6 receptor affinity
RS63661B1 (sr) Piridopirimidini kao inhibitori histaminskog h4-receptora
WO2009043884A1 (en) Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
EP4731216A1 (en) Heteroaryl-amine compounds and use thereof as hdac6 inhibitors
WO2026027696A1 (en) Thiomethyl carbonyl compounds and use thereof as hdac6 inhibitors
AU2022378269A1 (en) Quinazoline derivative compound and use thereof
CA2716202A1 (en) Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors
WO2025236004A1 (en) Stat6 inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141014